Uterine Fibroid Treatment Drugs Market - By Drug Class (Progestin-releasing Intrauterine Device, Contraceptive, Gonadotropin-releasing Hormone Antagonist), Type (Submucosal, Intramural), Distribution Channel (Retail, Hospital), Global Forecast, 2023-2032

Uterine Fibroid Treatment Drugs Market - By Drug Class (Progestin-releasing Intrauterine Device, Contraceptive, Gonadotropin-releasing Hormone Antagonist), Type (Submucosal, Intramural), Distribution Channel (Retail, Hospital), Global Forecast, 2023-2032

Uterine Fibroid Treatment Drugs Market Size

Uterine Fibroid Treatment Drugs Market size was valued to be USD 1.7 billion in 2022 and is projected to reach USD 4.5 billion by 2032 with a remarkable CAGR of 10%.  The expansion can be credited to significant elements like the rising occurrence of uterine fibroids, the emergence of novel medications for individuals with uterine fibroids, and the heightened consciousness regarding uterine fibroids.
 

Uterine fibroids, also known as leiomyomas or myomas, refers to non-cancerous tumors or growth developed in the muscular wall of the uterus and are the most common type of benign tumors that affects the female reproductive system. Uterine fibroid treatment drugs are medications are provided to alleviate the symptoms of uterine fibroids or to prepare the patient for surgical interventions. These drugs facilitate in reducing the symptoms such as heavy menstrual bleeding, pain, and pressure by targeting the hormonal regulation of fibroid growth.
 

COVID-19 Impact

During the pandemic, numerous healthcare systems found themselves overwhelmed while dealing with COVID-19 patients. As a result, many non-urgent medical procedures, including interventions related to uterine fibroids, had to be postponed or even cancelled. This situation notably affected the usage of uterine fibroid drugs like GnRH agonists, commonly employed to shrink fibroids before surgical procedures. The manufacturing and distribution processes of several pharmaceutical companies were severely impacted due to lockdowns and travel restrictions.
 

Consequently, these challenges led to disruptions in the pharmaceutical supply chain, which encompassed products for uterine fibroid treatment as well. The availability of such drugs suffered, resulting in an adverse impact on the global market for uterine fibroid treatment drugs. Throughout the pandemic, the significance of telemedicine became evident as it allowed patients to receive a certain level of medical care remotely.
 

As the number of COVID-19 cases decreases, there has been a gradual return to normal operations in healthcare facilities and pharmaceutical manufacturing. This positive trend is contributing to the increased adoption and availability of women health devices and treatment, including those designed for uterine fibroid treatment.
 

Uterine Fibroid Treatment Drugs Market Driving Factors

The growth of the market is being propelled by several factors, including the increasing prevalence of uterine fibroids, the development of new drugs tailored for women with these fibroids, and the growing awareness surrounding this condition. According to an article titled "A Look at the Current State of Uterine Fibroid Care," published in Contemporary OB/GYN in 2022, it is estimated that by the age of 50, more than 70% of women will have experienced uterine fibroids.
 

Furthermore, data from the U.S. National Institutes of Health (NIH) indicates that uterine fibroids affect 20-25% of women of reproductive age. Notably, the impact is more pronounced in different racial groups, with up to 80% of black women and up to 70% of white women being affected by uterine fibroids by the age of 50. Although most commonly observed in women in their 40s and early 50s, uterine fibroids can also develop in younger women.
 

Given the rising incidence of uterine fibroids, there is an increasing demand for more effective and safer treatment drugs. This demand has spurred the development of innovative uterine fibroid treatment medications to meet the needs of the affected population.
 

Uterine Fibroid Treatment Drugs Market Analysis

Based on drug class, the uterine fibroid treatment drugs market is segmented into progestin-releasing intrauterine device (IUD) & contraceptives, gonadotropin-releasing hormone (GnRH) antagonists, gonadotropin-releasing hormone (GnRH) agonists, non-hormonal medications, and other drug classes. Among the drug class, progestin-releasing intrauterine device (IUD) & contraceptives held significant market share of 65.7% in 2022 and is expected to growth at a CAGR of 9.9% over the coming years. The progestin-releasing intrauterine device (IUD)& contraceptives offers several advantages in managing the uterine fibroids, including reduced menstrual bleeding, pain relief, shrinking of fibroids, effective birth control and minimal side effects. In addition to this, this drug class provide long-term symptom relief as they remain effective for a long time and is suitable for women with different age groups. All these factors collectively aid in boosting the growth of this segment.
 

Based on the type, the uterine fibroid treatment drugs market is classified into submucosal fibroids, intramural fibroids, subserosal fibroids, and pedunculated fibroids. In 2022, the submucosal fibroids segment was valued to be USD 608.8 million and is expected to reach USD 1,589 million by 2032. Submucosal fibroids are particularly known for causing heavy menstrual bleeding, the progestins or GnRH agonists drug classes are widely used to manage the excessive bleeding by regulating hormones and controlling the growth of fibroids. During the forecast period, intramural fibroids are anticipated to grow at fastest CAGR as they can significantly contribute to infertility and pregnancy complications, hence treating such type of fibroids is crucial.
 

Based on the distribution channel, the uterine fibroid treatment drugs market is divided into retail pharmacies, hospital pharmacies, and other distribution channels. The retail pharmacies accounted for highest business share of 77.3% in 2022. The non-hormonal medications, contraceptives, NSAIDs, and other drugs are easily available in retail stores. Moreover, most of the patients with uterine fibroids are treated in outpatient settings except those who require surgery, leading to an increasing purchase of such drugs from retail pharmacies. Additionally, the availability of medications and increasing demand for safe and effective treatment in retail pharmacies is impacting the growth of retail pharmacies segment.
 

The North American uterine fibroid treatment drugs market is expected to grow at CAGR of 9.4% during the forecast period. Some of the factors contributing to the growth includes increasing prevalence of uterine fibroid, increasing demand for non-invasive, safe and effective treatment option, and better healthcare accessibility. Additionally, the presence of key players, approval of novel drugs, and increasing awareness related to the disease are expected to propel the market trends. The Asia Pacific region is expected to grow at highest CAGR of 10.9% during the forecast period because of the increasing prevalence of uterine fibroid in this region.
 

Uterine Fibroid Treatment Drugs Market Share

The key players in the uterine fibroid treatment drugs market are

• Pfizer Inc.
•  Abbvie, Inc.
• AstraZeneca plc
•  Bayer AG
•  Myovant Sciences Gmbh
• Ferring B.V.
• Amring Pharmaceuticals Inc.
• Theramex and Watson Pharma, Inc.

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
 

Uterine Fibroid Treatment Drugs Industry News

• In August 2022, MYFEMBREE, a product jointly developed by Pfizer, Inc. and Myovant Sciences, gained approval from the U.S. FDA for the management of moderate to severe pain associated with both menstrual and non-menstrual conditions. This regulatory endorsement facilitated their product's introduction to the market, thereby enriching their product portfolio.
   
• In June 2022, the European Commission approved the Yselty of Theramex, which is an oral GnRH antagonist. This strategy helped the company to strengthen its product portfolio and boosted their revenue.
   

The global uterine fibroid treatment drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

Market Size, By Drug Class

• Progestin-releasing intrauterine device (IUD)& contraceptives
• Gonadotropin-releasing hormone (GnRH) antagonists
• Gonadotropin-releasing hormone (GnRH) agonists
• Non-hormonal medications
• Other drug classes

Market Size, By Type

• Submucosal fibroids
• Intramural fibroids
• Subserosal fibroids
• Pedunculated fibroids

Market Size, By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Other distribution channels

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Switzerland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa